SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia
Sibylle C. Mellinghoff, Sandra Robrecht, Leonie Mayer, Leonie M. Weskamm, Christine Dahlke, Henning Gruell, Kanika Vanshylla, Hans Schlößer, Martin Thelen, Anna‐Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M. Addo, Barbara Eichhorst, Michael Hallek, Petra Langerbeins
Abstract
[1] conducted a large follow-up analysis of COVID-19 in patients with chronic lymphocytic leukemia (CLL) and confirmed a high mortality rate, especially in patients with older age, comorbidity and previous CLL-treatment. The results emphasize the importance of prevention and mitigation of COVID-19 by vaccination, especially in patients with hematological malignancies. The COVID-19 vaccine-induced immunity is mediated by the interaction of both, humoral and cellular components While several studies have confirmed low humoral immunogenicity in CLL patients In this prospective cohort study, we hence investigated cellular immunogenicity and the interplay with humoral immunogenicity following COVID-19 vaccination in SLL/CLL patients as compared with healthy controls (HC).